GIA
CPRX

GHP Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

GHP Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.7K Hold
1,201
– – ﹤0.01% 610
2026
Q1 		$29.7K Buy
1,201
+1
+0.1% +$24 ﹤0.01% 640
2025
Q4 		$28K Hold
1,200
– – ﹤0.01% 599
2025
Q3 		$23.6K Hold
1,200
– – ﹤0.01% 609
2025
Q2 		$26K Hold
1,200
– – ﹤0.01% 593
2025
Q1 		$29.1K Hold
1,200
– – ﹤0.01% 558
2024
Q4 		$25K Hold
1,200
– – ﹤0.01% 572
2024
Q3 		$23.9K Hold
1,200
– – ﹤0.01% 597
2024
Q2 		$18.6K Hold
1,200
– – ﹤0.01% 606
2024
Q1 		$19.1K Hold
1,200
– – ﹤0.01% 594
2023
Q4 		$20.2K Hold
1,200
– – ﹤0.01% 572
2023
Q3 		$15.3K Hold
1,200
– – ﹤0.01% 641
2023
Q2 		$17.9K Hold
1,200
– – ﹤0.01% 602
2023
Q1 		$19.9K Hold
1,200
– – ﹤0.01% 585
2022
Q4 		$22.3K Hold
1,200
– – ﹤0.01% 567
2022
Q3 		$15K Hold
1,200
– – ﹤0.01% 611
2022
Q2 		$8K Hold
1,200
– – ﹤0.01% 717
2022
Q1 		$10K Buy
+1,200
New +$8.48K ﹤0.01% 713

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GHP Investment Advisors's CPRX Position: Q2 2026 in Review

GHP Investment Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 1,201 shares worth $37.7K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

GHP Investment Advisors first reported a position in CPRX in Q1 2022 and has held it in 18 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • GHP Investment Advisors held 1,201 shares of Catalyst Pharmaceutical worth $37.7K as of Q2 2026.
  • GHP Investment Advisors left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #610 holding.
  • GHP Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 18 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.